References
- Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389(10065):1–10.
- Smilowitz NR, Gupta N, Guo Y, et al. Management and outcomes of acute myocardial infarction in patients with chronic kidney disease. Int J Cardiol. 2017;227:1–7.
- Amdur RL, Feldman HI, Dominic EA, et al. Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study. Am J Kidney Dis. 2019;73(3):344–353.
- Jankowski J, Floege J, Fliser D, et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–1172.
- Bagai A, Schulte PJ, Granger CB, et al. Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. Am Heart J. 2014;168(4):503–511.e502.
- Hartman MHT, Eppinga RN, Vlaar PJJ, et al. The contemporary value of peak creatine kinase-MB after ST-segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality. Clin Cardiol. 2017;40(5):322–328.
- Ndrepepa G, Colleran R, Braun S, et al. Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2018;91(2):215–223.
- Roe MT, Mahaffey KW, Kilaru R, et al. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J. 2004;25(4):313–321.
- Sun L, Wang Y, Zhang N, et al. High-sensitive cardiac troponin T for prediction of cardiovascular outcomes in stable maintenance hemodialysis patients: a 3-year prospective study. Kidney Blood Press Res. 2021;46(4):484–494.
- DeFilippi CR, Herzog CA. Interpreting cardiac biomarkers in the setting of chronic kidney disease. Clin Chem. 2017;63(1):59–65.
- Ren D, Huang T, Liu X, et al. High-sensitive cardiac troponin for the diagnosis of acute myocardial infarction in different chronic kidney disease stages. BMC Cardiovasc Disord. 2021;21(1):100.
- Yang H, Liu J, Luo H, et al. Improving the diagnostic accuracy of acute myocardial infarction with the use of high-sensitive cardiac troponin T in different chronic kidney disease stages. Sci Rep. 2017;7:41350.
- Glarner N, Lopez-Ayala P, Cakal H, et al. Applying high-sensitivity cardiac troponin T. J Am Coll Cardiol. 2021;78(18):e147.
- Engel G, Rockson SG. Rapid diagnosis of myocardial injury with troponin T and CK-MB relative index. Mol Diagn Ther. 2007;11(2):109–116.
- Mohammad MA, Koul S, Lonborg JT, et al. Usefulness of high sensitivity troponin T to predict long-term left ventricular dysfunction after ST-elevation myocardial infarction. Am J Cardiol. 2020;134:8–13.
- Sun L, Tan X, Cao X, et al. Assessed value of high-sensitivity cardiac troponin T for cardiovascular disease among CKD patients. Ren Fail. 2016;38(5):728–737.
- Dubin RF, Li Y, He J, et al. Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol. 2013;14:229.
- Chaulin AM. Cardiac troponins metabolism: from biochemical mechanisms to clinical practice (literature review). Int J Mol Sci. 2021;22(20):10928.
- Chauin A. The main causes and mechanisms of increase in cardiac troponin concentrations other than acute myocardial infarction (part 1): physical exertion, inflammatory heart disease, pulmonary embolism, renal failure, sepsis. Vasc Health Risk Manag. 2021;17:601–617.
- Yuan L, Chen C, Feng Y, et al. High sensitivity cardiac troponin, a cardiac marker predicting death in patients with kidney disease: a dose-response meta-analysis of cohort studies. QJM. 2022;116(5):335–343.
- Bajaj NS, Singh A, Zhou W, et al. Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in patients with chronic kidney impairment. Circulation. 2020;141(1):21–33.
- Felker GM, Fudim M. Unraveling the mystery of troponin elevation in heart failure. J Am Coll Cardiol. 2018;71(25):2917–2918.
- Weil BR, Suzuki G, Young RF, et al. Troponin release and reversible left ventricular dysfunction after transient pressure overload. J Am Coll Cardiol. 2018;71(25):2906–2916.
- Chaulin A. Clinical and diagnostic value of highly sensitive cardiac troponins in arterial hypertension. Vasc Health Risk Manag. 2021;17:431–443.
- Wilhelm J, Hettwer S, Schuermann M, et al. Elevated troponin in septic patients in the emergency department: frequency, causes, and prognostic implications. Clin Res Cardiol. 2014;103(7):561–567.
- Dohi T, Maehara A, Brener SJ, et al. Utility of peak creatine kinase-MB measurements in predicting myocardial infarct size, left ventricular dysfunction, and outcome after first anterior wall acute myocardial infarction (from the INFUSE-AMI trial). Am J Cardiol. 2015;115(5):563–570.
- Lopes RD, Lokhnygina Y, Hasselblad V, et al. Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. Trials. 2013;14:123.